All In Biotech

Drug Trial Radar · NCT04555486

Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients

A Phase 1 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of DCR-PHXC in Patients With Primary Hyperoxaluria Type 3

Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

Sep 14, 2020

Primary completion

Sep 7, 2021

Study completion Sep 7, 2021

Sponsor

Sponsor type
Industry
First posted
Sep 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The DCR-PHXC-104 study is designed to assess the safety, tolerability, and pharmacological parameters of a single dose of DCR-PHXC in Primary Hyperoxaluria Type 3 (PH3). Participants should have had at least one stone event within 12 months of screening and intact renal function.

Conditions

  • Primary Hyperoxaluria Type 3

Interventions

  • DCR-PHXCDrug

    Intervention, drug, DCR-PHXC

  • Sterile Normal Saline (0.9% NaCl)Drug

    Placebo comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety profile of a single dose of DCR-PHXC in PH3 PatientsTime frame: Screening through Day 85

Locations

6 sites in 4 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    Rochester, Minnesota

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    Bonn, Germany

  • Clinical Trial Site

    Amsterdam, Netherlands

  • Clinical Trial Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.